Mouse Monoclonal FXI antibody. Suitable for WB and reacts with Human samples. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human F11.
IgG2
Mouse
Constituents: PBS
Liquid
Monoclonal
WB | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 - 1/1000 | Notes - |
Select an associated product type
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
Coagulation factor XI, FXI, Plasma thromboplastin antecedent, PTA, F11
Mouse Monoclonal FXI antibody. Suitable for WB and reacts with Human samples. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human F11.
Coagulation factor XI, FXI, Plasma thromboplastin antecedent, PTA, F11
IgG2
Mouse
Constituents: PBS
Liquid
Monoclonal
MM0193-7C38
Affinity purification Protein G
The IgG fraction of culture supernatant was purified by Protein G affinity chromatography and lyophilized from a 0.2 µm filtered solution.
Blue Ice
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
Factor XI (FXI) also known as Factor 11 or Factor Eleven is an important protein in the human body involved in blood coagulation. It has a molecular mass of approximately 160 kDa and is primarily expressed in the liver. Factor XI circulates in the blood as a zymogen an inactive enzyme precursor until it is activated during the coagulation process. Its activation is a critical step in the chain of events leading to blood clot formation. FXI can be measured using assays such as ELISA and it is often used in laboratory settings to study coagulation mechanics.
FXI plays a significant role in the intrinsic pathway of the coagulation cascade. It forms a complex with high-molecular-weight kininogen and prekallikrein on the surface of activated platelets ensuring that the coagulation process proceeds efficiently. Upon activation by Factor XIIa FXI itself becomes an active serine protease known as FXIa which then converts Factor IX into its active form Factor IXa. This step highlights the importance of FXI in amplifying the coagulation process ensuring rapid and effective hemostasis.
Factor XI is deeply integrated into the intrinsic coagulation cascade. It works alongside other proteins such as Factor XII and Factor IX to facilitate the formation of a blood clot. The intrinsic pathway is essential for maintaining hemostasis particularly in response to internal injuries within the blood vessels. Its interaction with these proteins allows for a powerful amplification of the clotting signal ensuring a robust clot formation and effectively sealing vascular injuries.
Dysfunction or deficiency in FXI can lead to bleeding disorders such as Hemophilia C although this is less common than Hemophilia A or B. Interestingly elevated levels of FXI are sometimes associated with an increased risk of thrombotic conditions such as deep vein thrombosis or stroke. In these conditions FXI interacts with other coagulation factors like Factor IX and Factor XII highlighting its dual role in both bleeding and clotting disorders. Understanding FXI's role provides insight into therapeutic targets for managing these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-FXI antibody [MM0193-7C38] (ab89335) at 1/500 dilution
All lanes: Human placenta tissue lysate
Predicted band size: 70 kDa
Observed band size: 69 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com